Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL.
Introduction
Peripheral T-cell lymphomas (PTCL), a subdivision of T-cell non-Hodgkin's lymphomas (NHLs) and distinct from the more common cutaneous T-cell lymphomas, are a diverse group of disorders that for the most part carry a poor prognosis. Classification of PTCL is complex, has resulted in many classification schemes, and has been further hampered by a paucity of molecular markers. Older lymphoma classification systems include the Rappaport system, which was used until the mid 1970s, 1 the Kiel system, introduced in 1974, 2 and the National Cancer
Institute's Working Formulation (IWF), introduced in the 1980s. 3 The work of Lukes,
Collins,and Lennert in the 1970's first suggested that the T-cell lymphomas should be identified as distinct from B-cell lymphoma, but this was initially met with skepticism. In 1994, the International Lymphoma Study Group (ILSG) proposed the REAL classification (revised European-American Classification of Lymphoid Neoplasms), which featured the major histologic, immunologic, and genetic characteristics of B-and T-cell neoplasms and Hodgkin's lymphoma. 4 A clinical evaluation of the ILSG classification of NHL published in 1997
concluded that the classification could be readily applied and identified clinically distinctive types of NHL. 5 The International Lymphoma Epidemiology Consortium (InterLymph) proposed in 2007 a nested classification of lymphoid neoplasm subtypes. 6 They based their classification on the World Health Organization (WHO) classification of lymphoid neoplasms 7 and the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). 8 The fourth edition of the
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues was published in
2008. 9 The new WHO classification includes many additional subtypes of PTCL (Table 1) ;
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From nevertheless, it does not necessarily help clinicians determine the best therapeutic strategy for each specific subtype. The International PTCL Project is a collaborative effort that was designed to gain better understanding of the distribution and outcomes of aggressive T-cell lymphomas. A total of 22 institutions and over 1300 eligible patients in North America, Europe, and Asia participated in and submitted clinical and pathologic information on PTCL diagnosed and treated at their respective centers. 10 Treatment advances in PTCL have been slow when compared to other lymphomas. Very often, PTCL patients are treated with the same therapy used in B-cell lymphomas, but this approach generally has a very poor outcome. Relapse is common following the administration of most currently available agents, and there are few effective options for salvage therapy. In addition, only small numbers of patients have each type of PTCL, which further complicates studying new treatments for these diseases in clinical trials.
Classification
The WHO classification system classifies the mature T-cell lymphomas into four groups based on their clinical features. Most of the aggressive T-cell lymphomas are included within the nodal, extranodal, and leukemic groups.
The nodal lymphoma group includes PTCL, not otherwise specified (NOS), accounting for 25.9% of cases, 10 anaplastic large cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL). ALCL is further separated into the ALK + and ALK -entities. The ALK from the systemic ALCLs. Angioimmunoblastic T-cell lymphoma is the second largest category, accounting for 18.5% of cases in the International T-cell project. 10 The lymphoepithelioid cell variant appears to be distinct from the others and is usually characterized by CD8 + T cells and a predominance of epithelioid cells in the background. 12 The extranodal group includes a number of less common entities described primarily by their tissue tropism. Hepatosplenic gamma-delta T-cell lymphoma is a disease of children and young adults 13,14 accounting for 1.4% of PTCL cases. 10 This tumor is derived from immature or non-activated gamma-delta T cells which infiltrate the liver, spleen, and bone marrow sinusoids.
A characteristic chromosomal abnormality is isochromosome 7q, and patients with hepatosplenic T-cell lymphoma often have a poor outcome with a median survival of less than 2 years. The disease is more common in young males who often present with B-symptoms and cytopenias. Enteropathy-associated T-cell lymphoma (EATL) accounts for 4.7% of cases of T-cell lympoma. 10 EATL is more common in geographic areas with a higher incidence of celiac disease, as evidenced by the fact that it represents 5.8% and 9.1% of the PTCLs in North America and Europe, but only 1.9% of those in Asia. The disease often presents with pain, weight loss, and bowel perforation. There are two morphologic variants that are the pleomorphic type, associated with celiac disease and usually CD3 + ,CD7 + and CD56 -, and the monomorphic type, which is CD56 + and often not associated with celiac disease. 15 Chromosomal abnormalities found in EATL include gains at chromosome 9q33-q34 in up to 70% of cases. 16 The intestinal T-and NK-cell lymphomas diagnosed in Asian countries are associated with
Epstein-Barr virus (EBV) infection and are part of the spectrum of nasal-type natural killer
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From (NK/T) cell lymphoma. 17 The mucocutaneous gamma-delta T-cell lymphomas, 18 the nasal type NK/T cell lymphomas, and even ALCL can present as an intestinal lymphoma. 19, 20 Panniculitis-like T-cell lymphomas constitute only 0.9% of PTCLs, and in the International Peripheral T-cell Lymphoma Project were more common in men (75% of cases) than in women. Patients usually present with subcutaneous nodules that may become necrotic. The leukemia group consists of adult T-cell lymphoma (ATL) associated with human Tlymphotropic virus type I (HTLV-1), T-cell chronic large granular lymphocytic (LGL) leukemia, aggressive NK-cell leukemia, and T-cell prolymphocytic leukemia. Most patients with LGL leukemia have an indolent disorder that is often associated with neutropenia and that can be treated with immunosuppressive agents, while those with aggressive NK cell leukemia and ATL often have a poor outcome.
Several other types are delineated in the WHO classification: hydroa vacciniforme-like lymphoma, which is usually of a T-cell origin, NK-cell lymphoma caused by mosquito bite allergy, and systemic EBV-positive T-cell lymphoproliferative disease of childhood, which is part of the spectrum of chronic, active EBV infection.
Incidence of T-cell Lymphomas
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Based on the US SEER registry, the incidence of PTCL is less than 1 case per 100,000 people in the United States. 22 Results from the International PTCL Project showed that around the world, the most common subtypes are the nodal T-cell lymphomas, with PTCL-NOS (25.9%) being the most frequent, along with angioimmunoblastic T-cell lymphomas (18.5%) and the anaplastic large-cell lymphomas (12%). NK/T-cell lymphomas comprised 10.4%, while enteropathy-associated T-cell lymphomas (4.7%), hepatosplenic T-cell lymphomas (1.4%), and panniculitis-like T-cell lymphomas (0.9%) were rare, even in this large study. Among the common subtypes, there are regional differences in frequency. PTCL-NOS is more common in North America and less common in the European and Asian countries; AITL is more common in Europe than in Asia or North America; ALK + ALCL is more common in North America; ALK -ALCL is slightly more common in Europe; and the NK/T-cell lymphomas and ATL are more common in Asia. 23 The epidemiology of EATL is closely associated with the human leukocyte antigen DQ, which results in either overt or silent celiac disease, a European disease. 24 The EBVassociated lymphoproliferative, T-cell, and NK-cell neoplasms are seen mainly in Japan, Korea, and Northern China, but also in Native American populations from Central and South America.
NK-cell nasal and nasal-type lymphomas, occurring more frequently in Asia and Latin America, have a greater incidence in males than in females.
Viral associations with T-cell lymphomas
The increased incidence of T/NK cell lymphomas in East Asia related to the frequency of endemic HTLV-1 and Epstein-Barr viral infections. The HTLV-1 virus was first identified by Gallo's group at the National Cancer Institute from a cell line established from a patient with cutaneous T-cell lymphoma. 25 At the same time, Yoshida et al in Japan identified a retrovirus 
Prognostic Features of T-cell Lymphomas
Overall, patients with PTCL had a very poor outcome when compared to patients with aggressive B-cell lymphomas. 10 The International T-cell Lymphoma Study demonstrated that the overall survival (OS) and failure-free survival (FFS) with PTCL-NOS at 10 to 15 years was 10%
( Figure 1 ). The International Prognostic Index (IPI), when applied to patients with aggressive Tcell lymphomas, identified a group with high IPI score who had an adverse outcome compared to patients with low IPI, similar to diffuse large B-cell lymphoma. 35 However, even patients in the 1 0 best prognostic category did not have a favorable outcome, and patients in the highest risk category had very short survival. When examined by histopathologic subset, the 5-year OS for patients with PTCL-NOS and AITL with IPI of 0-1 were 56% and 50%, respectively, whereas those with IPI of 4 or 5 were 11% and 25%, respectively. For patients with ALCL, the 5-year survivals for IPI 0-1 patients were excellent at 90% and 74% for ALK+ and ALK-patients, respectively; however, patients with IPI of 4-5 had a poor outcome with 5-year survivals of 33%
and 13% , suggesting that IPI is an important predictor, even in ALK+ patients. 23 The IPI has not been predictive of outcome in patients with ATLL, enteropathy associated and hepatosplenic Tcell lymphoma, or extranasal NK/T cell lymphoma.
A new prognostic index specifically designed for PTCL, 36 the prognostic index for PTCL (PIT), is similar to the IPI, including age, LDH, performance status, and then bone marrow involvement. When applied to patients with PTCL-NOS, the index separated patients into more specific prognostic groups than the IPI. Of 322 patients studied, 20% had no adverse features, 34% had one feature, 26% had two features, and 20% had three or more. The 5-year overall survival for the most favorable group with no adverse prognostic features was 62% compared to 18% for patients with 3 or 4 adverse prognostic factors.
Aside from conventional histopathology, chemokine expression and proliferative signature have been shown to have prognostic significance, including p53 and Ki-67 ( Table 2 ).
In one study, p53 was the most important prognostic factor and was correlated with expression of p-glycoprotein, which confers resistance to chemotherapy. 37 In addition, 40%-60% of patients with PTCL express BCL2 and BCLX L associated proteins. 38 ALK + ALCL is usually BCL2
negative, while other subtypes with worse outcomes may be BCL2 + .
1
Two chemokine receptors, CXCR3 and CCR4, were found to be expressed in 63% and 34% of PTCL-NOS cancers, respectively. 8 The dominant chemokine expression found in this study was CXCR3-positive/CCR4-negative; this phenotype was shown by multivariate analysis to be an independent prognostic factor and significantly prognostic of a poor prognosis in both PTCL-NOS and ALK-negative ALCL.
In a study reported by Rudiger et al of PTCL-NOS category, which excludes AITL, the presence of >70% transformed blasts, >25% Ki67 proliferation, CD56 and CD30 expression, EBV infection, and a background of >10% CD8 + cells were all adverse prognostic factors. 39 The results indicated that immunophenotyping is absolutely necessary to determine prognosis. In another study, multivariate analysis of all prognostic factors indicated that, upon controlling for IPI, if the number of transformed cells is >70%, the hazard ratio for OS is 2.2 and 1.6 for FFS.
40
In patients with ALCL, the presence of the small cell variant can be associated with a worse prognosis. Finally, the expression of cytotoxic molecules also has an adverse impact on survival.
41
Gene expression, cytogenetic and comparative genomic hybridization data Several studies of gene expression profiling of PTCLs have been published. Importantly, expression profiling of purified normal T-cell subpopulations has provided the framework for understanding cell-of-origin and functional properties of T-cell malignancies. [42] [43] [44] [45] [46] [47] In aggregate, these studies have helped define the normal counterpart of several specific PTCLs, identified pathways frequently altered in PTCL, including NF-κB signaling and cell cycle deregulation, and highlighted the importance of proliferation as a potential biomarker for prognosis. [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] However, most of these studies are largely underpowered to allow definitive statements regarding survival
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More recently, gene expression profiling studies of larger numbers of patients have been undertaken and do provide novel insights into several PTCL entities. 58, 59 Iqbal and colleagues studied 144 cases and were able to confirm several previous observations. 58 Additionally they were able to show a major role for the microenvironment in AITL and developed a 15-gene outcome predictor highly correlated with survival and independent of the IPI. Similarly they Classical cytogenetic studies have also provided insight into copy number alterations in PTCL (Table 3) . 60 A recent study of PTCL-NOS, AITL, and ALK -ALCL revealed recurrent alterations associated with specific entities including gains of 5q, 21, and 3q in AITL, commonly associated with trisomies of chromosome 5 and 21. Loss of genetic material involving chromosome 6q was also frequent. ALK -ALCL was characterized by gains of 1q and 3p and losses of 16pter, 6q13-21, 15, 16qter, and 17p13. PTCL-NOS showed frequent gains of 7q22-31, 1q, 3p, 5p, and 8q24qter and losses of 6q22-24 and 10p13pter. Cases with a complex karyotype had shorter overall survival.
3
While many subtypes of PTCL are characterized by clonal expansion of TCR rearranged lymphocytes, this may not be a characteristic of all cases of NK neoplasms. Two studies recently examined the lack of TCR rearrangements in these patients and reported rearrangements at the TCR locus in 0.8%-1.2% of cases.
61,62
Comparative genomic hybridization (CGH) was used to examine genomic alterations in patients with ALK + and ALK -ALCL. A study of 74 patients showed that ALK + ALCL samples had gains of 17p and losses of 4q13-q21 and 11q14, whereas gains of 1q and 6p21 were more frequent in ALK -samples. 11 Another study, which used genomic profiling in patients with PTCL-NOS (n = 42) and ALK -ALCL (n = 37), 63 showed that genetics of PTCL-NOS and ALK -ALCL differ substantially from other T-cell lymphomas, including EATL, T-cell prolymphocytic leukemia (PLL), and ATL. Those with PTCL-NOS had recurrent chromosomal gains, high-level amplifications, and recurrent chromosomal losses on 13q, 6q, 9p, 10q, 12q, and 5q. Cutaneous ALCL and ALK + ALCL did not show imbalances, whereas ALK -ALCL showed chromosomal gains of 1q and losses of 6q and 13q.
Lastly, it is likely that significant progress in our understanding of the genetic complexity of PTCL will require an international effort to study a number of well annotated cases using next-generation sequencing strategies. 64 It can safely be hypothesized that this approach will yield important information about recurrent mutations and novel fusions that underlie the critical events in the biology of these tumors. Matched constitutional DNA will be required to properly annotate all of the somatic changes.
Therapeutic approaches
Standard first-line therapy 1 4 T-cell lymphomas have traditionally been treated much like the B-cell lymphomas, with a combination chemotherapy regimen. CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was the most widely used, although there were no randomized studies that proved that it was the best therapy. A retrospective meta-analysis of 2912 patients treated with CHOP or CHOP-like regimens reported a 5-year overall survival of 37%. 65 Several groups have tried more intensive chemotherapeutic treatments for PTCL patients. The French Groupe d'Etude des Lymphomes de l'Adulte (GELA) used more intensive chemotherapy-ACVBP (dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus consolidation with autologous stem cell transplant (ASCT) for younger, fitter patients. 66 The German High Grade
Non-Hodgkin's Lymphoma Study Group (DSHNHL) used several variations of CHOP, 67, 68 and
an Italian group used high-dose sequential chemotherapy with ASCT 69 The MD Anderson
Cancer Center used an alternating triple therapy regimen and hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone). 70 The GELA demonstrated that ACVBP had higher toxicity but superior event-free survival (EFS) and OS compared to CHOP. 71 CHOP-14 proved superior to CHOP-21 or CHOP + etoposide (CHOEP) in elderly patients, 68 and CHOEP should be used in younger patients . 67 Anthracycline-containing regimens for PTCL have been associated with median 5-year OS rates less than 40%. 65 ALCL patients have better outcomes than non-ALCL patients, with an overall response rate (ORR) over 75% and 5-year OS rates over 60%. 23 with aggressive T-cell lymphomas are less responsive to conventional B-cell lymphoma regimens, but data is emerging regarding the expression of p-glycoprotein and other drug resistance pathways in subsets of patients, particularly patients with NK/T-cell lymphomas.
Novel approaches
New therapeutic approaches and the incorporation of novel agents into these therapeutic regimens are necessary to improve the outcome for PTCL patients. Table 4 lists some of the new agents that are currently being used or are in clinical trials.
Monoclonal antibodies and immunoconjugates
The addition of the anti-CD20 monoclonal antibody (MAb) rituximab to chemotherapy regimens like CHOP has significantly improved treatment outcomes in B-cell lymphoma. As such, several monoclonal antibodies and targeted immunoconjugates and fusion proteins are currently being tested in PTCL, including alemtuzumab, iratumumab, siplizumab, zanolimumab, denileukin diftitox, and brentuximab vedotin.
Alemtuzumab, an anti-CD52 MAb, has been shown to have activity in heavily treated patients with PTCL with an ORR of 36% in one early study. 72 Alemtuzumab has been used in combination with CHOP or EPOCH (etoposide, prednisone, vincristine, cyclophophamide, and doxorubicin) with some success in PTCL, with half of patients achieving a complete response (CR). 73, 74 Another study compared combinations of alemtuzumab with CHOP, EPOCH, and CD4 is expressed in half of all T cells and by most CTCL and nodal PTCL cells.
Zanolimumab, an anti-CD4 MAb, is being used in both disease types, though clinical development for CTCL is farther along. Zanolimumab was shown to be active and well-tolerated in a study of 21 PTCL patients, with an ORR in 24% of patients. 86 Clinical studies of 1 7 zanolimumab in combination with CHOP are ongoing and include a phase I/II dose escalation trial in patients with noncutaneous CD4 + PTCL.
Bevacizumab, an antivascular endothelial growth factor (VEGF) MAb, will most likely have the largest impact in AITL, as AITL is characterized by the overexpression of angiogenic factors, such as VEGF. At least one relapsed AITL patient has achieved a CR following treatment with bevacizumab, 87 and was being studied along with CHOP in a clinical trial for patients with PTCL or NK-cell neoplasms by the Eastern Cooperative Oncology Group.
However, preliminary results of this trial reported a high incidence of cardiac events related to the therapy. 88 Denileukin diftitox , a fusion protein that combines interleukin-2 receptor-binding domain with diphtheria toxin, has demonstrated activity in both cutaneous and aggressive T-cell lymphomas. In a single center phase II study at MD Anderson Cancer Center, denileukin diftitox at a dose of 18 µg/kg/day for 5 days on a 21 day cycle demonstrated a response rate of 48% in heavily pretreated patients with relapsed PTCL. 89 Responses were seen in 4 of 10 patients with PTCL-NOS, 2 of 3 with AITL, and 2 of 2 with ALCL. In this trial, the expression of CD25 by immunohistochemistry was not predictive of response to denileukin diftitox.
Based on these data, a combination of denileukin diftitox and CHOP was studied in untreated patients with PTCL. This study enrolled 49 patients. Denileukin diftitox was administered at 18 mcg/kg/day on Days 1 and 2 of each cycle, followed by CHOP chemotherapy on Day 3, and G-CSF support starting Day 4 of each 21-day cycle. 90 In 37 efficacy-evaluable patients (>2 cycles), the ORR was 86% (CR 75%). Median PFS was 15 months and 2-year estimated OS was 60%. A large randomized study comparing CHOP to denileukin diftitox with CHOP is being initiated.
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For personal use only. on September 14, 2017. by guest www.bloodjournal.org From LMB-2 is an anti-Tac (anti-CD25) single chain monoclonal antibody (Mab) conjugated to Pseudomonas toxin. LMB-2 has shown clinical activity in phase II trials in CLL, CTCL, and hairy cell leukemia. ATL is the PTCL subtype that is most sensitive to LMB-2, but clinical responses have been limited to do rapid disease progression after >95% tumor reduction and immunogenic reactions. 91 A phase II clinical trial for this population is being planned in which LMB-2 will be given after chemotherapy with fludarabine and cyclophosphamide.
Histone deacetylase inhibitors
Histone (range 1 to 12). Objective response rate was 39% overall or 55% for patients who received at least 2 cycles of therapy. The overall median duration of response was 8.3 months (range 1 The objective response rate in PTCL was 32% with 2 CR and a median response duration of 8.9+
mo, and 14% in CTCL, with a response duration of 9.1 months. A multicenter phase II registration trial of belinostat in relapsed PTCL patients is underway, and a cohort dose escalation study of oral belinostat is ongoing in patients with relapsed lymphoma.
Additive and synergistic activity has been demonstrated in vitro for combinations of HDACi with a number of agents, including topoisomerase inhibitors, bortezomib, and cytotoxic chemotherapy drugs and clinical trials are underway to explore the activity of these combinations in T-cell lymphomas.
Antifolates
Pralatrexate is a novel folate antagonist whose activity is associated with binding to the reduced folate carrier. 97 In a phase I/II dose escalation trial of pralatrexate in refractory lymphoma patients, the ORR was 31%, with response durations ranging from 3-26 months. 98 The response rate in that trial was 54% for patients with T-cell lymphomas. Based on these encouraging data, the PROPEL trial was initiated. In this trial, 111 patients with relapsed or
refractory PTCL were treated with pralatrexate weekly for 6 weeks on a 7-week cycle, The median prior therapies was 3, and 63% of patients had no response to their last line of therapy.
The ORR was 29% and the median response duration was 10.1 months. Five patients with relapsed/refractory PTCL who responded to single-agent pralatrexate went onto stem cell transplant. 99 Toxicities included mucositis in70% of patients and thrombocytopenia in 40%.
Pralatrexate 
Immunomodulators and immunosuppressants
Cyclosporine is an immunosuppressive agent that inhibits the NF-AT transcription complex, which activates the genes encoding cytokines and cell surface molecules involved in cell-to-cell communication and death. 100 Because AITL is characterized by immune dysregulation, cyclosporine was administered to 12 patients in a phase II trial. 101 Two-thirds (3 CRs, 5 PRs) of the patients responded, but there were 4 deaths. A phase II trial of cyclosporine in AITL was conducted by ECOG but closed early due to slow accrual.
Other immune modulating and antiangiogenic agents, including bevacizumab, 87 rituximab, 102 lenalidomide, and thalidomide, are also being explored as single agents and in combination with chemotherapy. A phase II study of lenalidomide at a dose of 25 mg/m 2 daily for 21 days of a 28 day cycle was conducted in 24 relapsed PTCL patients. 103 The overall response rate was 30% with a PFS of 95 days. Toxicities included neutropenia and thrombocytopenia in 20% and 33% of patients, respectively.
Nucleoside analogs
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Nucleoside analogs are chemotherapeutic agents that primarily inhibit DNA replication and repair. Gemcitabine is the most effective pyrimidine nucleoside analog in PTCL. It has been active both as a single agent 104, 105 and in combination with alemtuzumab 106 and bortezomib. 107, 108 The purine nucleoside analogs include cladribine, fludarabine, clofarabine, and nelarabine. Both cladribine and fludarabine have shown efficacy in PTCL, and clofarabine and nelarabine are currently in several clinical trials in T-cell lymphoma.
The metabolic enzyme inhibitors, which include deoxycoformycin (pentostatin) and forodesine, do not incorporate into DNA, unlike the other nucleoside analogs. Pentostatin inhibits adenosine deaminase, increasing the deoxyadenosine triphosphate pool, and forodesine inhibits phosphorylase, increasing the deoxyguanosine triphosphate pool. Both agents have shown some efficacy in CTCL. A phase I/II study of oral forodesine in relapsed and refractory CTCL patients reported a 53% overall response rate, and a phase II trial has been completed.
109

Proteasome inhibitors
Bortezomib, a proteasome inhibitor, has been well tolerated and active as a single agent in relapsed or refractory CTCL patients. 110 In a phase II study of bortezomib in relapsed CTCL or PTCL patients, the ORR was 67% with 2 CR and no grade 4 toxicity. 110 The GELA has conducted a phase II study of bortezomib with ACVBP chemotherapy in 57 untreated PTCL patients and has reported that 29 patients were withdrawn prematurely due to toxicity. 111 The
ORRs were similar to ACVBP alone. Bortezomib has been used in combination with gemcitabine + doxorubicin, 107, 108 and recent evidence shows that bortezomib may synergize with pralatrexate in T-cell lymphoma (see antifolates section above).
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Signaling inhibitors
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Enzastaurin is a selective inhibitor of protein kinase C (PKC), which acts in part through the AKT pathway. By targeting the PI3K/AKT pathways, enzastaurin inhibits cell proliferation, induces tumor cell apoptosis, and suppresses tumor-induced angiogenesis in CTCL cell lines. 113 Enzastaurin is currently in two phase II trials: one for patients with several types of NHL, including PTCL and CTCL, and another for relapsed CTCL patients.
Treatment approaches for HTLV-1 associated ATL and NK/T cell lymphomas
Optimal treatment approaches for patients with NK/T cell lymphoma have not yet been established. A phase I/II study of concurrent chemoradiotherapy for untreated localized NK/Tcell lymphoma was conducted in Japan. 114 Extranodal NK/T-cell lymphoma, nasal type, is generally refractory to CHOP associated with a high expression of the multidrug resistance gene, P-glycoprotein. Patients in this trial were concurrently treated with radiotherapy and chemotherapy consisting of carboplatin, etoposide, ifosfamide, and dexamethasone. With a median follow-up of 32 months, the 2-year OS was 78% (95% CI, 57% to 89%). This compared favorably with the historical control of radiotherapy alone (45%). Of the 26 patients assessable for a response, 20 (77%) achieved a CR, with one PR. The ORR was 81%. The most common grade 3 nonhematologic toxicity was mucositis related to radiation (30%). The investigators concluded that concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma.
A novel approach for patients with advanced NK/T cell lymphomas incorporates Lasparaginase along with ifosfamide, etoposide, dexamethasone, and methotrexate (SMILE).
Overexpression of p-glycoprotein in NK/T cell lymphomas has contributed to relative chemoresistance and poor outcomes after CHOP-based therapies with 5-year survivals of 20% or 117 The study demonstrated superiority for VCAP-AMP-VECP for newly diagnosed aggressive ATL patients. A phase II study is in preparation to investigate the ability of allogeneic stem cell transplant after induction with the VCAP-AMP-VECP regimen to prolong the median survival time, which is currently 13 months with the VCAP-AMP-VECP regimen.
The use of interferon and zidovudine has been shown to induce responses in up to 50% of patients with acute or lymphomatous ATL. 118 In a recent meta-analysis, 116 patients with acute ATL, 18 patients with chronic ATL, 11 patients with smoldering ATL, and 100 patients with ATL lymphoma were evaluated. 119 Five-year OS rates were 46% for 75 patients who received first-line antiviral therapy (P=.004), 20% for 77 patients who received first-line chemotherapy, and 12% for 55 patients who received first-line chemotherapy followed by antiviral therapy. The
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From authors claimed that patients with acute, chronic, and smoldering ATL significantly benefited from first-line antiviral therapy, whereas patients with ATL lymphoma experienced a better outcome with chemotherapy. In acute ATL, 82% of patients were alive at 5 years with antiviral therapy, and 100% of patients with chronic and smoldering ATL were alive at 5 years.
Multivariate analysis showed that first-line antiviral therapy significantly improved overall survival (hazard ratio, 0.47; 95% CI, 0.27 to 0.83; P=.021). However,considering the potential selection bias in this retrospective study, future prospective studies are needed.
Finally, a humanized anti-CCR4 antibody, KW-0761, has shown promise as a single agent in Japan for the treatment of ATL. KW-0761 was used for relapsed patients with CCR4-positive ATL and PTCL in a phase I study. 120 The ORR was 31% (5/16; 95% CI, 11-59). There were no dose-limiting toxicities, and no anti-KW-0761 antibodies were detected. 120 A phase II trial for relapsed ATL patients was recently completed. Of 27 enrolled patients (14 acute, 6 lymphomatous, 7 chronic ATL), the ORR was 54% with 7 CR. Toxicities included cytopenias (lymphopenia 96%, neutropenia 33%), skin rash (52%), and mild transaminitis.
Transplantation
Several retrospective studies suggest that there are populations of patients with PTCL that will benefit from transplantation. The National Cancer Consortium Network (NCCN) guideline includes transplant as an option for consolidation after first remission in patients with histologies other than ALK+ ALCL and in patients with intermediate or high IPI scores. Disease status at transplant is a major predictor of success, particularly for autologous transplant. 121 Results are better for patients who are in chemosensitive remission, while only 25% to 30% of refractory patients benefit. 122, 123 In the studies where 5-year outcomes are reported, OS and FFS average 34% and 18%, respectively. 124 The single center experience at Stanford reported only a modest Further prospective studies are needed to define which subsets of PTCL patients will optimally benefit from allogeneic or autologous stem cell transplant.
Evidence-based treatment approaches for PTCL
Because of the inferior outcomes with CHOP-based regimens, novel strategies are needed for patients with aggressive T-cell lymphomas. The NCCN has established evidence-based treatment approaches for T-cell lymphoma and stratifies patients based on stage. For early stage patients with localized disease, chemotherapy should be followed by involved field radiotherapy.
It is recommended that all patients except for those with low IPI be consolidated with autologous stem cell transplant. ALK+ ALCL is identified as the one subtype which has an excellent outcome and should not be transplanted in first remission. Recent data suggest that ALK+ patients with high IPI could be an exception to this rule. In prospective trials where up to 40% of patients do not undergo a complete remission and therefore cannot be consolidated with transplant, new approaches are necessary.
Selection of first-line therapy based on histopathologic features has not yet been widely employed but should be considered. For nodal T-cell lymphomas (PTCL-NOS, AITL, ALCL) the standard regimen used is a CHOP-based therapy. For extranodal subtypes, regimens may be individualized. For panniculitis-like T-cell lymphoma, distinction should be made between the alpha-beta type and the gamma-delta type, which is now included in the category of cutaneous gamma-delta T-cell lymphoma. The alpha-beta patients may be treated with single-agent therapies or combination chemotherapy and generally have an excellent outcome. The cutaneous gamma-delta T-cell lymphomas overall do poorly and should be treated with aggressive chemotherapy followed by transplantation. Likewise, hepatosplenic and intestinal T-cell
have a poor outcome. In one study, 26 enteropathy-associated T-cell lymphoma patients were treated with CHOP then methotrexate alternating with ifosfamide, etoposide, and epirubicin. 128 Patients who achieved CR went on to transplant (n = 33). For the transplanted enteropathy-associated patients, the PFS and OS were 52% and 60%, respectively. NK/T-cell lymphoma patients have also had inferior outcomes with CHOP-based regimens, and consideration of alternative regimens such as SMILE and asparaginase combinations should be strongly considered for these patients.
The role of autologous vs allogeneic stem cell transplantation in patients with poor prognosis subtypes such as NK/T cell and gamma-delta T-cell lymphomas has not been ascertained. In retrospective series, results with these subtypes are inferior to those of the more common PTCL-NOS and AITL subtypes after autologous transplantation. Therefore, consolidation with allogeneic stem cell transplantation should be considered in patients who have appropriate donors.
Conclusion
From this summary of the current state of classification, prognosis, and therapeutic approaches in PTCL, it is apparent that much progress has been made. While the problem with PTCL treatment in the past was a lack of available therapies, the development of novel therapies 
registry is currently open and registering patients with newly diagnosed PTCL. Additionally, an international tissue bank has been initiated to capture sufficient quantities of clinically annotated and well-characterized specimens.
For 
